7Baggers

Galapagos NV
(NASDAQ:GLPG) 

GLPG stock logo

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ul...

Founded: 1999
Full Time Employees: 1,407
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-11-05 2025-07-24 2025-04-23 2025-02-12 2024-12-31 2024-10-30 2024-08-02 2024-05-02 2023-12-31 2023-11-02 2023-08-04 2023-05-04 2022-12-31 2022-11-07 2022-08-08 2022-05-06 2021-12-31 2021-11-08 2021-06-30 2020-12-31 2020-06-30 2020-05-11 2019-12-31 2019-10-25 2019-06-30 2019-04-26 2018-12-31 2018-10-26 2018-08-31 2018-04-27 2017-12-31 2017-07-31 2017-04-28 2016-12-31 2016-07-29 2016-03-03 2015-12-31 
                                         
      supply revenues
    		29,300 18,486,000 13,800 34,800,000 4,775,000 19,100,000 19.1                               
      collaboration revenues
    		182,100 121,779,000 61,200 240,800,000 59,786,000 181,000,000 121.2  239,357,200 366,800 274,500 152,200  349,700 238,600 121,936,000  311,700,000                    
      total net revenues
    		211,400 140,265,000 75,000 275,600,000 75,549,000 200,100,000 140.3 62,400,000 239,275,100 448,900 328,800 178,900  410,200 274,000 136,347,000                      
      cost of sales
    		-29,300 -18,435,000 -13,800  -15,763,000 -19,100,000  -2,500,000 -3,400 -13,600  -3,600   -5,500 -2,912,000                      
      r&d expenses
    		-351,900  -182,700  -59,550,000 -238,200,000  -71,600,000                              
      g&aiand s&miiexpenses
    		-109,000                                     
      impairment of the cell therapy business
    		-204,800                                     
      other operating result
    		21,400                                     
      operatingloss
    		-462,200                                     
      fair value adjustments and net exchange differences
    		-50,500  -9,400 95,800,000 63,995,000 31,800,000 49.5 30,600,000                              
      net other financial result
    		30,400  11,800 89,400,000 17,925,000 71,700,000 48.9 25,400,000 12,600 50,400 30,400 11,200      30,600,000                    
      income taxes
    		19,300 1,788,000 1,800 1,800,000 103,000 1,700,000 1.1 600,000 -9,599,500 -13,500  -300   -2,500   300,000 630,000  -373,000 -336,000 -16,913,000 16,828,000 -61,000 -68,000 -393,000 480,000 -75,000 -62,000  -92,000   24,000 1,218,000  
      net income from continuing operations
    		-463,000              -32,300    -64,329,000                 -118,410,000  
      net profit from discontinued operations, net of tax
    		1,700  1,100 75,400,000 17,300,000 69,200,000 71 66,700,000                              
      net profit/loss (-) of the period
    		-461,300  -153,400      13,525 54,100 28,300 23,200                          
      basic and diluted earnings/loss
    		-7,000  -2,300                                   
      financial investments, cash & cash equivalents
    		3,050,100  3,297,300 3,317.8                                  
      research and development expenses
    		 -278,027,000                         -91,117,000 -80,314,000          
      sales and marketing expenses
    		 -1,556,000              -28,984,000   -14,518,000  -17,086,000 -9,836,000 -14,878,000 -4,078,000 -3,875,000 -1,746,000 -2,234,000 -898,000 -602,000 -413,000  -1,090,000 -556,000  -876,000 -1,182,000  
      general and administrative expenses
    		 -72,914,000              -33,355,000   -46,436,000  -37,673,000 -24,902,000 -22,204,000 -28,565,000 -13,711,000 -9,221,000 -10,706,000 -9,725,000 -8,503,000 -6,697,000  -11,930,000 -5,603,000  -9,826,000 -19,127,000  
      other operating income
    		 14,932,000 6,600 40,800,000 15,973,000 24,800,000 16.6 9,400,000 47,231,900 40,100 23,800 8,300  29,500 17,600 7,680,000  36,300,000                    
      operating income
    		 -215,735,000 -158,700  -62,738,000 -125,600,000  -33,100,000 -88,244,000 -19,000     -97,500 -21,146,000   -46,750,000  -86,214,000 -44,585,000   -44,367,000 -53,242,000   -33,750,000 -32,036,000  -32,903,000 -11,225,000  -24,349,000 -89,444,000  
      yoy
    		 71.76%   -28.90% 660952.63%         -99.79%      94.32% -16.26%   31.46% 66.19%   200.67%   -63.21%      
      qoq
    		 135838.88%   -50.05%   -62.49% 464342.11%      -99.54%      93.37%    -16.67%    5.35%   193.12%   -72.78%   
      operating margin %
    		NaN% -Infinity% -Infinity% NaN% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% NaN% -Infinity% -Infinity% NaN% 0% -Infinity% NaN% -Infinity% -Infinity% NaN% NaN% -Infinity% -Infinity% NaN% NaN% -Infinity% -Infinity% NaN% -Infinity% -Infinity% NaN% -Infinity% -Infinity%  
      fair value adjustments and net currency exchange differences
    		 -66,228,000       9,050 36,200 200 -9,700                          
      other financial income
    		 22,536,000              15,058,000   -10,927,000  -25,435,000 39,722,000 -18,923,000 34,755,000        2,319,000 894,000  2,081,000   
      other financial expenses
    		 -1,364,000              -5,312,000   -8,140,000  -2,431,000 -24,873,000 -17,623,000 -38,631,000        -18,573,000 -3,274,000  -3,006,000   
      profit/loss (–) before tax
    		 -260,791,000                                    
      net profit/loss (–) from continuing operations
    		 -259,003,000                                    
      net profit/loss (–) from discontinued operations, net of tax
    		 -148,000                                    
      net profit/loss
    		 -259,151,000                                    
      g&ai and s&mii expenses
    		  -43,800                                   
      net profit/loss (-) from continuing operations
    		  -154,500  -5,100,000 -20,400,000 28.2 23,500,000                              
      g&aii and s&miii expenses
    		    -23,300,000 -93,200,000  -30,800,000 -45,550 -182,200  -58,100   -134,000                       
      net profit of the year
    		   74,100,000                                  
      basic and diluted earnings per share
    		   1.12 0.175 0.7 1.51 1.4                              
      net profit of the period
    		    12,200,000 48,800,000 99.2 90,200,000                              
      current financial investments, cash & cash equivalents
    		    834.7 3,338.8 3,430.4 3,557.9                              
      product net sales
    		        20,525 82,100 54,300 26,700  60,500 35,400 14,411,000  6,100,000                    
      r&d expenditure
    		        -78,050 -312,200  -103,500   -249,500                       
      basic and diluted income/loss
    		        205 820 430 400                          
      current financial investments and cash and cash equivalents
    		        952,925 3,811,700 3,874,900 3,990,100  4,362.1 4,429   4,874.2                    
      operating profit/loss
    		          11,300 22,000                          
      net financial result
    		             127,500 67,700                       
      net profit from discontinued operations
    		                 22,200,000                    
      net income of the period
    		              -32,300                       
      basic and diluted loss per share
    		              -0.49       -0.78    -0.89    -0.73        
      basic and diluted loss per share from continuing operations
    		              -0.49                     -3.32  
      research and development expenditure
    		               -99,921,000   -138,866,000  -149,114,000 -116,763,000 -74,561,750 -120,680,000 -94,372,000 -83,195,000   -81,680,000 -69,765,000  -92,913,000 -44,930,000  -62,412,000 -129,714,000  
      fair value re-measurement of warrants
    		               -185,000   858,000  -589,000 -20,529,000                
      loss before tax
    		               -11,586,000   -64,959,000  -114,669,000 -50,266,000   -47,188,000 -48,588,000   -21,698,000 -37,221,000      -119,627,000  
      total revenues
    		                 317,900,000                    
      yoy
    		                                     
      qoq
    		                                     
      fair value re-measurement of financial instruments
    		                 3,000,000                    
      net loss of the period
    		                                     
      revenues
    		                     98,173,000 181,429,750 633,934,000  33,047,000 45,614,250 94,874,000  37,907,000  60,925,000 33,992,000  38,795,000 39,563,000  
      other income
    		                  13,298,000  14,059,000 8,743,000 24,161,000 10,020,000 8,852,000 7,872,000 6,386,000 8,334,000 7,358,000 6,931,000  12,106,000 5,871,000  9,969,000 21,017,000  
      total revenues and other income
    		                  153,070,000  117,659,000 106,916,000 143,427,000 643,954,000 67,590,000 40,919,000 112,765,000 103,208,000 57,034,000 44,838,000  73,031,000 39,863,000  48,764,000 60,579,000  
      total operating expenses
    		                  -199,820,000  -203,873,000 -151,501,000 -166,155,000 -153,323,000 -111,958,000 -94,161,000 -104,057,000 -90,937,000 -90,784,000 -76,875,000  -105,933,000 -51,088,000     
      net income from discontinued operations, net of tax
    		                                     
      net income
    		                     -50,601,000    -48,656,000    -37,283,000        
      yoy
    		                     4.00%    30.50%            
      qoq
    		                                     
      net income margin %
    		NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 0% NaN% NaN% NaN% -Infinity% NaN% NaN% NaN% -Infinity% NaN% NaN% NaN% -Infinity% NaN% NaN% NaN% NaN% NaN% NaN%  
      net loss attributable to:
    		                                     
      owners of the parent
    		                    -115,042,000 -50,601,000 -115,484,000 361,233,000 -47,249,000 -48,656,000 14,956,000 14,841,000 -21,773,000 -37,283,000  -49,249,000 -13,605,000  32,229,000 -118,410,000  
      operating profit / loss
    		                      98,255,250 490,631,000              
      fair value re-measurement of share subscription agreement
    		                      -35,587,250 -142,349,000           57,479,000   
      profit / loss (–) before tax
    		                      62,157,500 344,405,000        -49,157,000 -13,605,000     
      net profit / loss
    		                      66,332,250 361,233,000              
      net profit / loss (–) attributable to:
    		                                     
      basic gain / loss (–) per share
    		                      1.193 6.26   -0.215 0.29          
      diluted gain / loss (–) per share
    		                      1.148 6.03   -0.215 0.28          
      financial income
    		                        -1,349,000 6,999,000 2,666,750 2,558,000 6,499,000 1,610,000        
      financial expenses
    		                        -1,472,000 -2,345,000 -427,000 -467,000 5,553,000 -6,794,000        
      operating gain / loss
    		                          -13,378,750 12,271,000          
      gain / loss (–) before tax
    		                          -11,139,250 14,362,000          
      net gain / loss
    		                          -11,053,750 14,841,000          
      net gain / loss (–) attributable to:
    		                                     
      weighted-average number of shares – basic and diluted
    		                             50,973        
      net income / loss
    		                               -49,249,000 -13,605,000  32,229,000 -118,410,000  
      net income / loss (–) attributable to:
    		                                     
      basic income / loss (–) per share
    		                               -1.03 -0.29     
      diluted income / loss (–) per share
    		                               -1.03 -0.29     
      weighted-average number of shares – basic
    		                               48,043 46,256     
      weighted-average number of shares – diluted
    		                               49,987 48,330     
      profit / loss (-) before tax
    		                                  32,205,000   
      net income / loss (-) attributable to:
    		                                     
      basic income / loss (-) per share
    		                                  0.71   
      diluted income / loss (-) per share
    		                                  0.69   
      weighted-average number of shares - basic
    		                          52,113    49,479    45,229   
      weighted-average number of shares - diluted
    		                          52,113    49,479    46,756   
      restructuring and integration costs
    		                                     
      non-cash adjustment on financial assets
    		                                   -30,632,000  
      other finance result
    		                                   448,000  
      net income from discontinued operations
    		                                     
      basic and diluted income / loss (-) per share
    		                                   -3.32  
      weighted-average number of shares
    		                                   35,700  
      consolidated statement of comprehensive income
    		                                     
      items that will not be reclassified subsequently to profit or loss:
    		                                     
      remeasurement of defined benefit obligation
    		                                   202  
      items that may be reclassified subsequently to profit or loss:
    		                                     
      translation differences, arisen from translating foreign activities
    		                                   690  
      translation differences, arisen from the sale of service division
    		                                     
      other comprehensive income, net of income tax
    		                                   892  
      total comprehensive income attributable to:
    		                                     
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-11-05 2025-07-24 2025-04-23 2024-12-31 2024-10-30 2024-05-02 2023-12-31 2023-11-02 2022-05-06 2021-12-31 2021-06-30 2020-12-31 2020-06-30 2020-05-11 2019-10-25 2019-06-30 2019-04-26 2018-10-26 2018-08-31 2018-04-27 2017-07-31 2017-04-28 2016-12-31 2016-07-29 2016-03-03 
                               
        assets
      		                         
        goodwill
      		 69,151,000 69,712,000  69,465,000 69,715,000  69,863,000                  
        intangible assets other than goodwill
      		7,422,000 147,427,000 156,252,000 164,862,000 173,431,000 125,998,000 127,906,000 132,313,000                  
        property, plant and equipment
      		105,617,000 109,686,000 113,225,000 122,898,000 132,234,000 125,059,000 126,321,000 136,803,000 145,896,000 137,512,000 111,900,000 103,378,000 73,786,000 66,979,000 61,883,000 51,180,000 49,542,000 18,113,000 17,854,000 16,971,000 15,506,000 15,064,000 14,961,000 15,091,000 13,782,000 
        deferred tax assets
      		838,000 870,000 1,473,000 1,474,000 1,153,000 1,107,000 1,126,000 1,232,000 4,037,000 4,032,000 4,451,000 4,475,000 4,207,000 4,206,000  2,516,000 2,511,000 2,525,000 1,980,000 1,979,000 1,957,000 1,957,000 1,957,000 1,756,000 1,726,000 
        non-current r&d incentives receivables
      		116,997,000 115,330,000 113,194,000 132,729,000 133,401,000 144,775,000 141,252,000 138,121,000 132,650,000 127,186,000 117,278,000 111,624,000 102,790,000 93,156,000 89,965,000 82,644,000 76,029,000 68,755,000 71,567,000 69,285,000 61,242,000 58,693,000 54,188,000 54,492,000 49,384,000 
        non-current contingent consideration receivable
      		48,919,000 50,645,000 42,175,000 42,465,000 42,726,000 42,739,000                    
        equity investments
      		46,844,000 46,928,000 50,855,000 52,941,000 49,125,000                     
        other non-current assets
      		2,490,000 2,527,000 2,706,000 8,708,000 11,239,000 65,516,000 29,645,000 16,911,000 7,881,000 2,473,000 4,422,000 11,343,000 9,523,000 13,945,000 5,993,000 5,712,000 6,377,000 2,474,000 2,506,000 2,182,000 2,697,000 2,878,000 2,880,000 536,000 557,000 
        convertible loan
      		20,766,000 20,348,000                        
        non-current financial investments
      		   200,182,000                      
        non-current assets
      		349,893,000 562,912,000 549,592,000 796,269,000 612,774,000 574,909,000 495,807,000 495,244,000 349,615,000 331,306,000 301,123,000 348,384,000 229,559,000 212,142,000 200,739,000  140,956,000 95,151,000        
        inventories
      		22,948,000 33,794,000 38,516,000 51,192,000 65,563,000 80,558,000 73,978,000 55,605,000 18,398,000 20,569,000        280,000 267,000 293,000 318,000 324,000 300,000 322,000 325,000 
        trade and other receivables
      		45,330,000 55,499,000 51,148,000 47,476,000 45,426,000 54,611,000 28,449,000 46,918,000 61,694,000 111,337,000 88,133,000 148,418,000 31,351,000 27,096,000 32,642,000 42,067,000 15,347,000 25,314,000 19,108,000 8,501,000 5,383,000 16,010,000 9,728,000 7,262,000 3,931,000 
        current r&d incentives receivables
      		32,342,000 32,342,000 32,342,000 39,882,000 41,801,000 37,436,000 37,436,000 26,126,000 16,827,000 16,827,000 25,467,000 24,104,000 13,839,000 22,084,000 9,746,000 11,644,000 11,645,000 11,692,000 14,654,000 11,585,000 10,259,000 10,154,000 10,154,000 10,363,000 9,161,000 
        current financial investments
      		2,985,656,000 3,019,835,000 3,189,235,000 3,053,334,000 3,283,256,000 3,484,560,000 3,517,698,000 3,652,333,000 3,389,098,000 2,469,809,000 2,363,969,000 3,026,278,000 3,182,276,000 2,978,805,000            
        cash and cash equivalents
      		64,458,000 71,669,000 108,067,000 64,239,000 55,523,000 73,372,000 166,803,000 159,375,000 1,254,279,000 2,233,368,000 2,642,639,000 2,135,187,000 2,384,220,000 2,743,573,000 5,599,787,000 1,147,923,000 1,222,901,000 1,343,668,000 1,066,766,000 1,108,186,000 1,262,061,000 953,385,000 973,241,000 960,481,000 340,314,000 
        escrow account
      		 21,819,000 21,728,000 41,163,000 40,880,000 40,222,000                    
        other current assets
      		11,287,000 20,354,000 31,318,000 31,049,000 26,979,000 15,711,000 15,140,000 15,735,000 10,403,000 9,945,000 9,286,000 11,953,000 10,319,000 8,705,000 8,837,000 6,970,000 9,351,000 7,432,000 7,086,000 7,171,000 6,936,000 8,215,000 7,239,000 6,982,000 5,512,000 
        current assets from continuing operations
      		3,162,021,000 3,255,312,000 3,472,354,000 3,328,335,000 3,559,428,000 3,786,470,000 3,839,504,000   4,861,854,000 5,129,494,000 5,345,941,000              
        assets in disposal group classified as held for sale
      		   11,115,000   22,085,000                   
        total current assets
      		3,162,021,000 3,255,312,000 3,472,354,000 3,339,450,000 3,559,428,000 3,786,470,000 3,861,589,000   4,861,854,000 5,129,494,000 5,369,347,000              
        total assets
      		3,511,914,000 3,818,224,000 4,021,946,000  4,172,202,000 4,361,379,000  4,451,336,000 5,100,315,000     5,992,406,000 5,851,752,000  1,400,200,000 1,485,551,000  1,229,864,000 1,368,355,000 1,072,814,000  1,066,524,000 442,514,000 
        equity and liabilities
      		                         
        share capital
      		293,937,000 293,937,000 293,937,000  293,937,000 293,937,000  293,937,000 292,592,000     288,106,000 272,605,000  237,348,000 235,672,000  235,027,000 233,018,000 223,928,000  223,149,000 185,399,000 
        share premium account
      		2,736,994,000 2,736,994,000 2,736,994,000 2,736,994,000 2,736,994,000 2,736,994,000 2,736,994,000 2,736,993,000 2,732,034,000 2,730,391,000 2,729,824,000 2,727,840,000 2,723,671,000 2,708,114,000 2,268,585,000 1,283,650,000 1,280,452,000 1,276,284,000 996,117,000 995,336,000 992,776,000 649,135,000 649,135,000 648,553,000 357,402,000 
        other reserves
      		-9,288,000 -9,215,000 -5,163,000 -3,158,000 -7,041,000 -5,530,000 -5,890,000 -4,932,000 -10,230,000 -10,177,000 -10,768,000 -10,907,000 -4,900,000 -4,919,000 -735,000 -735,000 -735,000 -641,000 -641,000 -641,000 -809,000 -1,008,000 -1,000,000 -18,000 -18,000 
        translation differences
      		3,058,000 2,899,000 2,939,000 3,472,000 3,128,000 2,687,000 -1,201,000 -1,196,000 -1,688,000 -1,722,000 -2,394,000 -3,189,000 -746,000 -663,000 -1,267,000 -1,505,000 -1,290,000 -1,598,000 -1,604,000 -1,757,000 -1,406,000 -1,051,000 -1,090,000 -1,039,000 -467,000 
        accumulated losses
      		-577,738,000 -380,796,000 -280,813,000 -134,306,000 -164,448,000 -133,080,000 -228,274,000 -403,242,000 -366,119,000 -367,205,000 -345,101,000 -334,701,000 -235,224,000 -150,597,000 -3,907,000 -376,518,000 -340,020,000 -321,495,000 -343,796,000 -328,620,000 -154,553,000 -122,854,000 -112,272,000 -140,845,000 -177,317,000 
        total equity
      		2,446,963,000 2,643,819,000 2,747,894,000 2,896,939,000 2,862,570,000 2,895,008,000 2,795,566,000 2,621,560,000 2,646,589,000 2,643,362,000 2,663,473,000 2,670,355,000 2,773,263,000 2,840,041,000 2,535,281,000 1,143,367,000 1,175,755,000 1,188,222,000 885,659,000 899,345,000 1,069,026,000 748,150,000 758,701,000 729,800,000 364,999,000 
        retirement benefit liabilities
      		2,107,000 2,109,000 2,078,000 2,099,000 2,291,000 2,270,000 2,293,000 2,408,000  11,699,000 15,031,000 14,996,000 8,511,000 8,444,000 4,026,000 3,939,000 3,851,000         
        deferred tax liabilities
      		 17,877,000 18,718,000 20,660,000 20,966,000 22,728,000 23,607,000 25,325,000                  
        non-current lease liabilities
      		5,764,000 6,050,000 7,787,000 8,243,000 7,240,000 3,837,000 4,944,000 8,469,000  19,655,000 21,429,000 23,035,000 20,384,000 18,856,000 19,661,000 20,457,000 20,409,000         
        other non-current liabilities
      		24,207,000 21,585,000 27,073,000 33,821,000 30,904,000 42,887,000 31,570,000 31,449,000  7,135,000 6,478,000 8,096,000 10,691,000 8,113,000 2,471,000 1,373,000 736,000 1,269,000 878,000 677,000 1,962,000 1,697,000 2,469,000 1,392,000 2,291,000 
        non-current deferred income
      		666,310,000 723,830,000 781,353,000 838,876,000 896,999,000 1,012,435,000 1,071,193,000 1,318,090,000  1,944,836,000 2,147,222,000 2,365,974,000 2,420,177,000 2,494,327,000 2,659,013,000   23,083,000 67,427,000 102,486,000 162,970,000 191,328,000 214,785,000 220,881,000  
        non-current liabilities
      		698,388,000 771,451,000 837,009,000 903,699,000 958,400,000 1,084,157,000 1,133,607,000 1,385,741,000  1,983,325,000 2,190,160,000 2,412,101,000 2,459,763,000 2,529,740,000 2,685,171,000 25,769,000 24,996,000 28,227,000 72,102,000 106,888,000 168,652,000 196,681,000 220,846,000 225,175,000 5,103,000 
        current lease liabilities
      		1,738,000 2,393,000 3,071,000 3,479,000 4,225,000 4,140,000 4,652,000 5,678,000  7,204,000 6,480,000 6,401,000 6,872,000   5,141,000 4,580,000         
        trade and other liabilities
      		100,633,000 133,179,000 168,944,000 98,877,000 115,858,000 145,551,000 135,201,000 121,129,000  137,418,000 151,721,000 172,386,000 179,432,000   86,216,000 69,880,000         
        provisions
      		33,722,000 36,868,000 34,199,000               57,000 58,000 65,000 57,000 64,000 63,000 51,000 55,000 
        current tax payable
      		349,000 278,000 195,000 249,000 216,000 62,000 56,000 1,764,000  1,782,000 377,000 1,248,000 1,262,000   1,031,000 1,168,000  862,000    1,022,000  2,583,000 
        current deferred income
      		230,121,000 230,236,000 230,634,000 232,476,000 230,933,000 232,461,000 256,270,000 315,465,000  419,866,000 418,071,000 443,159,000 403,656,000   96,325,000 123,822,000  175,722,000       
        current liabilities
      		366,563,000  437,043,000     444,036,000  566,474,000  635,274,000 618,538,000   188,712,000 199,450,000  246,586,000    103,791,000  72,412,000 
        total liabilities
      		1,064,951,000 1,174,405,000 1,274,052,000 1,238,780,000 1,309,632,000 1,466,371,000 1,561,830,000 1,829,776,000  2,549,798,000 2,767,144,000 3,047,375,000 3,078,301,000   214,481,000 224,445,000  318,688,000    324,637,000  77,515,000 
        total equity and liabilities
      		3,511,914,000 3,818,224,000 4,021,946,000  4,172,202,000 4,361,379,000  4,451,336,000         1,400,200,000        442,514,000 
        total current liabilities
      		 402,954,000  335,081,000 351,232,000 382,214,000 428,223,000    576,985,000               
        ​
      		                         
        current liabilities from continuing operations
      		   335,081,000 351,232,000 382,214,000 396,179,000   566,474,000 576,985,000 626,357,000              
        liabilities directly associated with assets in disposal group classified as held for sale
      		      32,044,000                   
        current assets
      		       3,956,092,000 4,750,700,000    5,622,005,000 5,780,264,000 5,651,013,000 1,208,604,000 1,259,244,000 1,390,400,000 1,107,881,000 1,135,735,000 1,284,957,000 992,122,000 1,007,232,000 992,267,000 374,470,000 
        intangible assets
      		        59,151,000     33,856,000 23,492,000  6,497,000 2,058,000  2,555,000 859,000 963,000  1,226,000 1,550,000 
        non-current trade receivables
      		           50,000,000              
        assets classified as held for sale
      		           23,406,000              
        current financial instruments
      		         204,000 336,000 3,164,000 27,316,000             
        liabilities directly associated with assets classified as held for sale
      		           8,917,000              
        non-current deferred tax assets
      		              19,406,000           
        non-currents assets
      		               149,244,000   96,467,000 94,129,000 83,398,000 80,692,000 76,107,000 74,257,000 68,044,000 
        non-current restricted cash
      		                 1,226,000 1,158,000 1,158,000 1,137,000 1,137,000 1,098,000 1,155,000 1,046,000 
        current restricted cash
      		                 2,014,000    4,034,000 6,570,000 6,858,000 6,857,000 
        pension liabilities
      		                 3,818,000 3,739,000 3,660,000 3,663,000 3,592,000 3,520,000 2,815,000 2,693,000 
        finance lease liabilities
      		                      9,000 37,000 63,000 
        trade and other payables
      		                  69,141,000    31,269,000  29,482,000 
        accrued charges
      		                  861,000    619,000  490,000 
        current financial asset from share subscription agreement
      		                         
        deferred income
      		                      70,827,000  39,806,000 
        current financial assets
      		                        8,371,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD 
         
          ​
        		 
          net profit/loss
        		 
          adjustment for non-cash transactions
        		 
          adjustment for items to disclose separately under operating cash flow
        		 
          adjustment for items to disclose under investing and financing cash flows
        		 
          change in working capital other than deferred income
        		 
          cash from other liabilities related to the acquisition/disposal of subsidiaries
        		 
          decrease in deferred income
        		 
          cash from operations
        		 
          interest paid
        		 
          interest received
        		 
          corporate taxes received/paid
        		 
          net cash flows from operating activities
        		 
          purchase of property, plant and equipment
        		 
          purchase of and expenditure in intangible fixed assets
        		 
          proceeds from disposal of property, plant and equipment
        		 
          purchase of financial investments
        		 
          investment income received related to financial investments
        		 
          sale of financial investments
        		 
          cash out from disposals of subsidiaries, net of cash disposed of
        		 
          cash out from acquisition of subsidiaries, net of cash acquired
        		 
          cash advances and loans to third parties
        		 
          acquisition of financial assets held at fair value
        		 
          net cash flows generated from/used in (-) investing activities
        		 
          payment of lease liabilities
        		 
          proceeds from capital and share premium increases from exercise of subscription rights
        		 
          net cash flows from financing activities
        		 
          decrease in cash and cash equivalents
        		 
          cash and cash equivalents at beginning of year
        		 
          effect of exchange rate differences on cash and cash equivalents
        		 
          cash and cash equivalents at end of year
        		 
          cash from other liabilities related to the acquisition of subsidiaries
        		 
          corporate taxes paid
        		 
          purchase of current financial investments
        		 
          investment income received related to current financial investments
        		 
          sale of current financial investments
        		 
          disposals of subsidiaries, net of cash disposed
        		 
          acquisition of financial assets held at fair value through profit or loss
        		 
          proceeds from sale of financial assets held at fair value through profit or loss
        		 
          increase/decrease (-) in cash and cash equivalents
        		 
          net income
        		 
          income taxes paid
        		 
          net cash flows used in operating activities
        		 
          interest received related to current financial investments
        		 
          acquisition of financial assets
        		 
          payment of lease liabilities and other debts
        		 
          net cash flows generated from/used in (-) financing activities
        		 
          net income/loss
        		 
          increase/decrease (-) in deferred income
        		 
          cash generated from/used in (-) operations
        		 
          net cash flows generated from/used in (-) operating activities
        		 
          proceeds from capital and share premium increases, gross amount
        		 
          issue cost paid, related to capital and share premium increases
        		 
          proceeds from capital and share premium increases from exercise of warrant a by gilead
        		 
          increase in cash and cash equivalents
        		 
          transfer to current financial investments
        		 
          cash generated/used (-) in operations
        		 
          net cash flows generated/used (-) in operating activities
        		 
          proceeds from disposal of intangible assets
        		 
          net cash flows generated/used (-) in investing activities
        		 
          net cash flows generated in financing activities
        		 
          the accompanying notes form an integral part of these financial statements.
        		 
          f-10
        		 
          current financial investments
        		 
          cash and cash equivalents
        		 
          cash and cash equivalents classified as assets held for sale
        		 
          current financial investments and cash and cash equivalents
        		 
          f-11
        		 
          increase / decrease (-) in deferred income
        		 
          increase in current financial investments
        		 
          decrease in current financial investments
        		 
          decrease in restricted cash
        		 
          net cash flows used in investing activities
        		 
          proceeds from capital and share premium increases from exercise of warrants
        		 
          net income / loss
        		 
          decrease (-) / increase in deferred income
        		 
          cash generated / used (-) in operations
        		 
          repayment of obligations under finance leases and other debts
        		 
          cash and cash equivalents at beginning of the period
        		 
          net cash flows generated / used (-) in operating activities
        		 
          net cash flows generated / used (-) in investing activities
        		 
          cash and cash equivalents at end of the period
        		 
          adjustments for:
        		 
          tax income (-) /expenses
        		 
          other net financial income
        		 
          fair value re-measurement of share subscription agreement
        		 
          depreciation of property, plant and equipment
        		 
          amortization of intangible fixed assets
        		 
          net realized gain / loss (-) on foreign exchange transactions
        		 
          share-based compensation
        		 
          increase / decrease (-) in provisions
        		 
          increase in pension liabilities
        		 
          gain on disposal of fixed assets
        		 
          gain on sale of service division
        		 
          operating cash flows before movements in working capital
        		 
          increase (-) / decrease in inventories
        		 
          increase in receivables
        		 
          increase / decrease (-) in payables
        		 
          cash generated / used (-) from operations
        		 
          income taxes paid (-) / received
        		 
          increase (-) / decrease in restricted cash
        		 
          acquisition of available-for-sale financial assets
        		 
          proceeds from capital and share premium increases, net of issue costs
        		 
          other financial income
        		 
          non-cash adjustment on financial assets
        		 
          net realized loss on foreign exchange transactions
        		 
          increase/decrease (-) in provisions
        		 
          gain on sale of fixed assets
        		 
          increase in inventories
        		 
          decrease in payables
        		 
          increase (-)/ decrease in restricted cash